These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 18307835)

  • 1. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
    Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Hsu H; Zhang J
    Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase.
    Sica D; Gradman AH; Lederballe O; Kolloch RE; Zhang J; Keefe DL
    Clin Drug Investig; 2011 Dec; 31(12):825-37. PubMed ID: 22035463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone.
    Geiger H; Barranco E; Gorostidi M; Taylor A; Zhang X; Xiang Z; Zhang J
    J Clin Hypertens (Greenwich); 2009 Jun; 11(6):324-32. PubMed ID: 19527323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan.
    Chrysant SG
    Drugs Today (Barc); 2010 Mar; 46(3):151-62. PubMed ID: 20467589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
    Moniwa N; Varagic J; Ahmad S; VonCannon JL; Simington SW; Wang H; Groban L; Brosnihan KB; Nagata S; Kato J; Kitamura K; Gomez RA; Lopez ML; Ferrario CM
    Hypertension; 2013 Feb; 61(2):417-24. PubMed ID: 23232645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension.
    Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Ritter S; Zhang J
    Curr Med Res Opin; 2010 Dec; 26(12):2841-9. PubMed ID: 21062137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of aliskiren/valsartan vs valsartan in nocturnal dipper and nondipper hypertensive patients: a pooled analysis.
    Giles TD; Alessi T; Purkayastha D; Zappe D
    J Clin Hypertens (Greenwich); 2012 May; 14(5):299-306. PubMed ID: 22533656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.
    Oparil S; Yarows SA; Patel S; Fang H; Zhang J; Satlin A
    Lancet; 2007 Jul; 370(9583):221-229. PubMed ID: 17658393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases.
    Yarows SA
    Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):19-33. PubMed ID: 20030022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aliskiren and valsartan combination therapy for the management of hypertension.
    Epstein BJ
    Vasc Health Risk Manag; 2010 Sep; 6():711-22. PubMed ID: 20859542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.
    Yarows SA; Oparil S; Patel S; Fang H; Zhang J
    Adv Ther; 2008 Dec; 25(12):1288-302. PubMed ID: 19066757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
    Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
    Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.
    Drummond W; Sirenko YM; Ramos E; Baek I; Keefe DL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):327-33. PubMed ID: 21846154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual inhibition of the renin system by aliskiren and valsartan.
    Oparil S; Yarows SA; Patel S; Zhang J; Satlin A
    Lancet; 2007 Sep; 370(9593):1126-7. PubMed ID: 17905160
    [No Abstract]   [Full Text] [Related]  

  • 16. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of add-on aliskiren to type 1 angiotensin receptor blocker therapy on endothelial function and autonomic nervous system in hypertensive patients with ischemic heart disease.
    Ozeki A; Amiya E; Watanabe M; Hosoya Y; Takata M; Watanabe A; Kawarasaki S; Nakao T; Watanabe S; Omori K; Yamada N; Tahara Y; Hirata Y; Nagai R
    J Clin Hypertens (Greenwich); 2014 Aug; 16(8):591-8. PubMed ID: 25039889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
    O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
    Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy.
    Tuomilehto J; Tykarski A; Baumgart P; Reimund B; Le Breton S; Ferber P
    Blood Press Suppl; 2008 Jun; 1():15-23. PubMed ID: 18705531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of the renin system by aliskiren and valsartan.
    Birkenhäger WH; Staessen JA
    Lancet; 2007 Jul; 370(9583):195-196. PubMed ID: 17658374
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 29.